Healthcare
Live Price
Offline$79.57
-2.25% today
1Y Change
-50.62%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zoetis Inc. (ZTS) is a Healthcare stock with a market cap of $47.57B and listed on NYSE. The stock last traded around $79.57 and down 50.6% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +2.3%, EPS growth of +10.2%, a dividend yield of 1.8%. What stands out right now is revenue +2.3%, EPS +10.2%, free cash flow -0.7% with operating margin 38.0% and ROIC 21.5%. The dividend is present but secondary, with a yield around 1.8%. Valuation sits in the middle of the pack at P/E 18.5 and price/sales 5.0. Stock Foundry combines ZTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZTS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZTS Max Drawdown
-53.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZTS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.8B
-3.8% YoY
FY Net Income
$2.0B
-3.6% YoY
Free Cash Flow
$1.7B
+30.9% YoY
Revenue Growth
+2.3%
EPS Growth
+10.2%
Gross Margin
70.5%
Net Margin
28.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 9.5B | 9.3B | 8.5B | 8.1B | 7.8B |
| Gross Profit | 6.7B | 6.4B | 5.8B | 5.5B | 5.3B |
| Operating Income | 3.6B | 3.4B | 3.1B | 2.9B | 2.8B |
| EBITDA | 4.1B | 3.9B | 3.7B | 3.4B | 3.2B |
| Net Income | 2.7B | 2.5B | 2.3B | 2.1B | 2.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.3B | 2.0B | 2.0B | 3.6B | 3.5B |
| Total Assets | 15.5B | 14.2B | 14.3B | 14.9B | 13.9B |
| Total Liabilities | 12.1B | 9.5B | 9.3B | 10.5B | 9.4B |
| Shareholder Equity | 3.3B | 4.8B | 5.0B | 4.4B | 4.5B |
| Total Debt | 9.5B | 6.7B | 6.8B | 8.1B | 6.7B |
| Net Debt | 7.2B | 4.8B | 4.7B | 4.5B | 3.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.2B
+15.7% YoY
Capital Expenditures
477M
+18.6% YoY
Free Cash Flow
1.7B
+30.9% YoY
Key ratios
Gross Margin
70.5%
Operating Margin
38.0%
Net Margin
28.2%
ROE
58.2%
Debt / Equity
2.85x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.